" class="no-js "lang="en-US"> Bio-Rad Introduces CFX Opus Deepwell Real-Time PCR Detection System - Medtech Alert
Friday, April 12, 2024

Bio-Rad Introduces CFX Opus Deepwell Real-Time PCR Detection System

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced the launch of the CFX Opus Deepwell Real-Time PCR Detection System to support researchers in developing nucleic acid detection assays.


The CFX Opus Deepwell System is the latest addition to the Bio-Rad portfolio of CFX Opus Real-Time PCR instruments. With a 96-well block and the largest reaction volume available in the CFX Opus range — up to 125 µl — the CFX Opus Deepwell System offers accurate, precise, and reliable quantification to support assay development. The deeper sample wells of the CFX Opus Deepwell System are designed for workflows that require larger reaction volumes for pooling, certain sample prep procedures, or other specialized protocols such as in food and industrial testing, and human and veterinary pathogen detection. The Deepwell System can multiplex up to five targets simultaneously and supports fluorescence resonance energy transfer (FRET) applications. The CFX Opus Systems deliver uniform thermal cycling and powerful software, which can be linked to Bio-Rad’s BR.io platform, providing remote setup, instrument monitoring, and cloud data management capabilities.


“We are witnessing an increasing demand for improved real-time PCR systems that offer more efficient workflows and enhanced data management and analysis,” said Steven Blakely, Director for Gene Expression and Software Technology, Bio-Rad. “We’re pleased to expand our portfolio of CFX Opus Detection Systems with the Deepwell format to help researchers perform experiments more efficiently and to consistently deliver robust datasets.”

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more